Lv1
20 积分 2025-10-29 加入
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2天前
已完结
Structure-based classification predicts drug response in EGFR-mutant NSCLC
2天前
已完结
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
5天前
已关闭
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
5天前
已完结
Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report
12天前
已完结
Erratum to ‘Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report’ [Journal of Thoracic Oncology Volume 20, Issue 5 (2025) 676-679]
12天前
已完结
Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry
12天前
已关闭
[Expert consensus on diagnosis and treatment of lung cancer complicated with interstitial lung disease]
13天前
已完结
Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease
13天前
已完结
[Research progress of interstitial lung disease combined with lung cancer]
13天前
已完结
皖公网安备34019202002308
